United Kingdom-based GW Pharmaceuticals expects to report annual sales of approximately $526 million for the year ended Dec. 31, 2020, it said in a preview of its fourth quarter and full-year results. Fourth quarter net sales will be approximately $148…
GW Pharma
Cannabis firm Canopy Growth sues GW Pharma, claiming patent infringement
Canadian cannabis producer Canopy Growth Corp. is suing Britain’s GW Pharmaceuticals in U.S. federal court, alleging that GW is knowingly infringing upon Canopy’s intellectual property. GW uses a Canopy-patented method to extract the CBD th…
Epidiolex maker GW reports record quarterly revenue of $137 million
United Kingdom-based GW Pharmaceuticals posted higher revenue in the quarter ended Sept. 30, largely driven by sales of its cannabidiol medicine Epidiolex in the United States. GW’s total revenue for the third quarter reached $137.1 million, abou…
DEA loosens rules on prescription CBD drug Epidiolex
Prescription CBD tincture Epidiolex is coming to more patients. Cost: $32,500 per year.
The post DEA loosens rules on prescription CBD drug Epidiolex appeared first on Leafly.